Estimates show melanoma diagnoses continuing to climb in the United States, even as newer therapies continue to reduce deaths from advanced disease.

Myqorzo was approved in December to treat adults with obstructive hypertrophic cardiomyopathy. It is available through a REMS program and has a boxed warning about the risk of heart failure.

Ten Medicaid tech companies pledge over $600 million in support to help states meet new community engagement requirements and modernize eligibility systems.

A recent study found that older adults who received the shingles vaccine were biologically younger than those who didn’t, which suggests the vaccine may slow aspects of biological aging as well as prevent shingles.

Explore the impact of ACA tax credits on enrollment, premiums and healthcare access as Congress debates subsidy extensions for 2026 and beyond.

Yuvezzi is the first combination product that treats adults with presbyopia. It will be available in the second quarter of 2026.